Analysts Set DaVita Inc. (NYSE:DVA) PT at $154.00

Shares of DaVita Inc. (NYSE:DVA) have been assigned a consensus recommendation of “Hold” from the five analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $157.00.

Several research analysts have commented on DVA shares. UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. TD Cowen lifted their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Barclays lifted their target price on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Monday, May 6th. Truist Financial lifted their target price on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Tuesday, August 20th. Finally, StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th.

Insider Buying and Selling

In related news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently bought and sold shares of DVA. 8 Knots Management LLC acquired a new position in DaVita in the fourth quarter valued at approximately $89,504,000. Doma Perpetual Capital Management LLC acquired a new position in DaVita in the fourth quarter valued at approximately $53,076,000. Harvard Management Co. Inc. acquired a new position in DaVita in the second quarter valued at approximately $55,115,000. Norges Bank acquired a new position in DaVita in the fourth quarter valued at approximately $36,626,000. Finally, Allianz Asset Management GmbH boosted its stake in DaVita by 63.9% in the fourth quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after acquiring an additional 213,992 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Trading Up 1.1 %

NYSE:DVA opened at $153.99 on Friday. The business’s 50-day moving average is $141.30 and its two-hundred day moving average is $136.20. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. DaVita has a 12 month low of $71.51 and a 12 month high of $155.56. The firm has a market capitalization of $13.50 billion, a PE ratio of 17.50, a price-to-earnings-growth ratio of 0.87 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. During the same period last year, the company posted $2.08 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. Research analysts predict that DaVita will post 9.9 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.